DYNLRB1 and bronchopulmonary dysplasia: Elevated bombesin-like peptide (BLP)/gastrin-releasing peptide (GRP) (Box 1) levels in PNECs have been proposed as an etiological agent of and a potential therapeutic target for BPD.